Ramelteon - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)Enzymes (3)

Targets (2)Enzymes (3)Biointeractions (5)

Identification

Name

Ramelteon

Accession Number

DB00980 (APRD01213)

Type

Small Molecule

Groups

Approved, Investigational

Description

Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Not Available

External IDs

TAK-375 / TAK375

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Rozerem	Tablet, film coated	8 mg/1	Oral	Rebel Distributors	2005-07-22	Not applicable	US
Rozerem	Tablet, film coated	8 mg/1	Oral	bryant ranch prepack	2005-07-22	Not applicable	US
Rozerem	Tablet, film coated	8 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-05-18	2017-09-20	US
Rozerem	Tablet, film coated	8 mg/1	Oral	Takeda	2005-07-22	Not applicable	US
Rozerem	Tablet, film coated	8 mg/1	Oral	Physicians Total Care, Inc.	2006-08-01	Not applicable	US
Rozerem	Tablet, film coated	8 mg/1	Oral	Avera Mc Kennan Hospital	2015-03-05	Not applicable	US

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Rozerem	Not Available

Brand mixtures

Not Available

Categories

UNII

901AS54I69

CAS number

196597-26-9

Weight

Average: 259.3434
Monoisotopic: 259.157228921

Chemical Formula

C₁₆H₂₁NO₂

InChI Key

YLXDSYKOBKBWJQ-LBPRGKRZSA-N

InChI

InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1

IUPAC Name

N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide

SMILES

CCC(=O)NCC[[email protected]@H]1CCC2=C1C1=C(OCC1)C=C2

Pharmacology

Indication

For the treatment of insomnia characterized by difficulty with sleep onset.

Structured Indications

Sleeplessness

Pharmacodynamics

Ramelteon is the first selective melatonin agonist. It works by mimicking melatonin (MT), a naturally occuring hormone that is produced during the sleep period and thought to be responsible for the regulation of circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has a high affinity for the MT₁ and MT₂ receptors. The MT₁ and MT₂ receptors are located in the brain's suprachiasmatic nuclei (SCN),which is known as the body's "master clock" because it regulates the 24-hour sleep-wake cycle. Ramelteon has an active metabolite that is less potent but circulates in higher concentrations than the parent compound. The metabolite also has weak affinity for the 5HT2b receptor.

Mechanism of action

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT₁ and MT₂ receptors, and lower selectivity for the MT₃ receptor. Melatonin production is concurrent with nocturnal sleep, meaning that an increase in melatonin levels is related to the onset of self-reported sleepiness and an increase in sleep propensity. MT₁ receptors are believed to be responsible for regulation of sleepiness and facilitation of sleep onset, and MT₂ receptors are believed to mediate phase-shifting effects of melatonin on the circadian rhythm. While MT₁ and MT₂ receptors are associated with the sleep-wake cycle, MT₃ has a completely different profile, and therefore is not likely to be involved in the sleep-wake cycle. Remelteon has no appreciable affinity for the gamma-aminobutyric acid (GABA) receptor complex or receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Melatonin receptor type 1B	Protein	yes	multitarget	Human	P49286	details
Melatonin receptor type 1A	Protein	yes	multitarget	Human	P48039	details

Absorption

Rapid, total absorption is at least 84%.

Volume of distribution

73.6 L

Protein binding

~82% (in human serum)

Metabolism

Hepatic

Route of elimination

Following oral administration of radiolabeled ramelteon, 84% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 88%. Less than 0.1% of the dose was excreted in urine and feces as the parent compound.

Half life

~1-2.6 hours

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ramelteon.	Experimental
Abiraterone	The serum concentration of Ramelteon can be increased when it is combined with Abiraterone.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ramelteon.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Aceprometazine is combined with Ramelteon.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when adipiplon is combined with Ramelteon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Agomelatine is combined with Ramelteon.	Approved, Investigational
Alfaxalone	The risk or severity of adverse effects can be increased when Alfaxalone is combined with Ramelteon.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Ramelteon.	Approved, Illicit
Allopregnanolone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Sage 547.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ramelteon.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Ramelteon.	Approved, Illicit, Investigational
Amiodarone	The serum concentration of Ramelteon can be increased when it is combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Amisulpride is combined with Ramelteon.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ramelteon.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Ramelteon.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Amoxapine is combined with Ramelteon.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Amperozide is combined with Ramelteon.	Experimental
Aprepitant	The serum concentration of Ramelteon can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon.	Approved, Investigational
Armodafinil	The metabolism of Ramelteon can be decreased when combined with Armodafinil.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Articaine is combined with Ramelteon.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Asenapine is combined with Ramelteon.	Approved
Atazanavir	The serum concentration of Ramelteon can be increased when it is combined with Atazanavir.	Approved, Investigational
Atomoxetine	The metabolism of Ramelteon can be decreased when combined with Atomoxetine.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Azaperone is combined with Ramelteon.	Vet Approved
Azelastine	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Ramelteon.	Approved
Azithromycin	The metabolism of Ramelteon can be decreased when combined with Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Ramelteon.	Approved
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Ramelteon.	Illicit
Benperidol	The risk or severity of adverse effects can be increased when Ramelteon is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Ramelteon.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ramelteon.	Approved
Bexarotene	The serum concentration of Ramelteon can be decreased when it is combined with Bexarotene.	Approved, Investigational
Boceprevir	The serum concentration of Ramelteon can be increased when it is combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Ramelteon can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Ramelteon can be decreased when it is combined with Bosentan.	Approved, Investigational
Brexpiprazole	The risk or severity of adverse effects can be increased when Ramelteon is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Ramelteon.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon.	Approved, Illicit
Brompheniramine	The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ramelteon.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Brotizolam is combined with Ramelteon.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ramelteon.	Approved, Investigational
Buprenorphine	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Ramelteon.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Butacaine is combined with Ramelteon.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Ramelteon.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Butamben is combined with Ramelteon.	Approved
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Ramelteon.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Ramelteon.	Approved, Illicit, Vet Approved
Caffeine	The metabolism of Ramelteon can be decreased when combined with Caffeine.	Approved
Capecitabine	The serum concentration of Ramelteon can be increased when it is combined with Capecitabine.	Approved, Investigational
Carbamazepine	The metabolism of Ramelteon can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ramelteon.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Ramelteon.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon.	Approved
Ceritinib	The serum concentration of Ramelteon can be increased when it is combined with Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Cetirizine is combined with Ramelteon.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ramelteon.	Approved, Illicit, Vet Approved
Chloramphenicol	The metabolism of Ramelteon can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ramelteon.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Ramelteon.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ramelteon.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorphenamine.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramelteon.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ramelteon.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ramelteon.	Approved
Cholecalciferol	The metabolism of Ramelteon can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cimetidine	The metabolism of Ramelteon can be decreased when combined with Cimetidine.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Ramelteon.	Approved, Vet Approved
Citalopram	The metabolism of Ramelteon can be decreased when combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Ramelteon can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Ramelteon can be decreased when combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Clidinium is combined with Ramelteon.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Clobazam is combined with Ramelteon.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when clomethiazole is combined with Ramelteon.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Ramelteon is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Ramelteon.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Ramelteon.	Approved, Illicit
Clotrimazole	The metabolism of Ramelteon can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Ramelteon.	Approved
Cobicistat	The serum concentration of Ramelteon can be increased when it is combined with Cobicistat.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Ramelteon.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Ramelteon.	Approved, Illicit
Conivaptan	The serum concentration of Ramelteon can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	The metabolism of Ramelteon can be decreased when combined with Crizotinib.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.	Approved
Cyclosporine	The metabolism of Ramelteon can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ramelteon.	Approved
Cyproterone acetate	The serum concentration of Ramelteon can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Dabrafenib	The serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Ramelteon.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Dapoxetine.	Investigational
Darunavir	The serum concentration of Ramelteon can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Ramelteon can be increased when it is combined with Dasatinib.	Approved, Investigational
Deferasirox	The serum concentration of Ramelteon can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Ramelteon can be increased when it is combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when deramciclane is combined with Ramelteon.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Ramelteon.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Desvenlafaxine.	Approved
Detomidine	The risk or severity of adverse effects can be increased when Detomidine is combined with Ramelteon.	Vet Approved
Dexamethasone	The serum concentration of Ramelteon can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ramelteon.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ramelteon.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ramelteon.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Ramelteon.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Ramelteon.	Approved, Illicit, Vet Approved
Difenoxin	The risk or severity of adverse effects can be increased when Ramelteon is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ramelteon.	Approved, Illicit
Dihydroergotamine	The metabolism of Ramelteon can be decreased when combined with Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ramelteon.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ramelteon.	Experimental, Illicit
Diltiazem	The metabolism of Ramelteon can be decreased when combined with Diltiazem.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Ramelteon is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ramelteon.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ramelteon.	Approved, Illicit
Doramectin	The risk or severity of adverse effects can be increased when Doramectin is combined with Ramelteon.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Ramelteon is combined with Doxepin.	Approved
Doxycycline	The metabolism of Ramelteon can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when DPDPE is combined with Ramelteon.	Investigational
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Illicit
Dronedarone	The metabolism of Ramelteon can be decreased when combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Ramelteon.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ramelteon.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Ramelteon.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Ramelteon is combined with Ecopipam.	Investigational
Efavirenz	The serum concentration of Ramelteon can be decreased when it is combined with Efavirenz.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Pregnanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Ramelteon.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Entacapone is combined with Ramelteon.	Approved, Investigational
Enzalutamide	The serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide.	Approved
Erythromycin	The metabolism of Ramelteon can be decreased when combined with Erythromycin.	Approved, Vet Approved
Escitalopram	The risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Ramelteon can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esomeprazole	The metabolism of Ramelteon can be decreased when combined with Esomeprazole.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Ramelteon.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Ramelteon.	Approved
Ethanol	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramelteon.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Ethotoin is combined with Ramelteon.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ramelteon.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ramelteon.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ramelteon.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Etidocaine is combined with Ramelteon.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Etifoxine is combined with Ramelteon.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Etizolam is combined with Ramelteon.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Ramelteon.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Ramelteon.	Illicit, Vet Approved
Etravirine	The serum concentration of Ramelteon can be decreased when it is combined with Etravirine.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Felbamate is combined with Ramelteon.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Ramelteon.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Ramelteon.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Fexofenadine is combined with Ramelteon.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Ramelteon is combined with Flibanserin.	Approved
Floxuridine	The serum concentration of Ramelteon can be increased when it is combined with Floxuridine.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ramelteon.	Approved, Illicit
Flumazenil	Flumazenil may decrease the sedative activities of Ramelteon.	Approved
Flunarizine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ramelteon.	Approved, Illicit
Fluorouracil	The serum concentration of Ramelteon can be increased when it is combined with Fluorouracil.	Approved
Fluoxetine	The metabolism of Ramelteon can be decreased when combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Ramelteon.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Ramelteon.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ramelteon.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ramelteon.	Approved
Fluvoxamine	The serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Ramelteon can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Ramelteon can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Ramelteon can be increased when combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Fospropofol is combined with Ramelteon.	Approved, Illicit
Fusidic Acid	The serum concentration of Ramelteon can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Ramelteon.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Ramelteon is combined with gabapentin enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ramelteon.	Approved, Illicit
Gemfibrozil	The serum concentration of Ramelteon can be increased when it is combined with Gemfibrozil.	Approved
Gepirone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Ramelteon.	Approved, Illicit
Guanfacine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Ramelteon.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Ramelteon.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Ramelteon.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ramelteon.	Approved
Hydrocodone	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved
Idelalisib	The serum concentration of Ramelteon can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Iloperidone.	Approved
Imatinib	The metabolism of Ramelteon can be decreased when combined with Imatinib.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Indalpine.	Investigational, Withdrawn
Indinavir	The serum concentration of Ramelteon can be increased when it is combined with Indinavir.	Approved
Isavuconazonium	The metabolism of Ramelteon can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Ramelteon.	Approved, Vet Approved
Isoniazid	The metabolism of Ramelteon can be decreased when combined with Isoniazid.	Approved
Isradipine	The metabolism of Ramelteon can be decreased when combined with Isradipine.	Approved
Itraconazole	The serum concentration of Ramelteon can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Ramelteon can be increased when it is combined with Ivacaftor.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Ramelteon.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Ketazolam is combined with Ramelteon.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Ramelteon.	Approved
Ketoconazole	The serum concentration of Ramelteon can be increased when it is combined with Ketoconazole.	Approved, Investigational
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Ramelteon is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ramelteon.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Ramelteon is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ramelteon.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Ramelteon.	Approved
Lidocaine	The metabolism of Ramelteon can be decreased when combined with Lidocaine.	Approved, Vet Approved
Lithium	The risk or severity of adverse effects can be increased when Lithium is combined with Ramelteon.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Ramelteon.	Illicit
Lopinavir	The serum concentration of Ramelteon can be increased when it is combined with Lopinavir.	Approved
Loratadine	The risk or severity of adverse effects can be increased when Loratadine is combined with Ramelteon.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Ramelteon.	Approved
Lovastatin	The metabolism of Ramelteon can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Ramelteon.	Approved
Luliconazole	The serum concentration of Ramelteon can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Ramelteon can be decreased when it is combined with Lumacaftor.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Vet Approved
Maprotiline	The risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Meclizine is combined with Ramelteon.	Approved
Medetomidine	The risk or severity of adverse effects can be increased when Medetomidine is combined with Ramelteon.	Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Ramelteon.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Melperone is combined with Ramelteon.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Ramelteon.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Ramelteon.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ramelteon.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Methapyrilene is combined with Ramelteon.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Methaqualone is combined with Ramelteon.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Ramelteon.	Approved
Methotrimeprazine	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ramelteon.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ramelteon.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ramelteon.	Approved
Metyrosine	Ramelteon may increase the sedative activities of Metyrosine.	Approved
Mexiletine	The metabolism of Ramelteon can be decreased when combined with Mexiletine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon.	Approved, Illicit
Mifepristone	The serum concentration of Ramelteon can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Ramelteon is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Investigational
Mirtazapine	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Ramelteon can be decreased when it is combined with Mitotane.	Approved
Moclobemide	The metabolism of Ramelteon can be decreased when combined with Moclobemide.	Approved
Modafinil	The serum concentration of Ramelteon can be decreased when it is combined with Modafinil.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Molindone is combined with Ramelteon.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Ramelteon.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Investigational
Nafcillin	The serum concentration of Ramelteon can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ramelteon.	Approved
Nefazodone	The serum concentration of Ramelteon can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Ramelteon can be increased when it is combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Ramelteon can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Ramelteon can be increased when combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Ramelteon can be increased when it is combined with Nicardipine.	Approved
Nilotinib	The metabolism of Ramelteon can be decreased when combined with Nilotinib.	Approved, Investigational
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ramelteon.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ramelteon.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Ramelteon is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Ramelteon.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ramelteon.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon.	Approved, Investigational
Olaparib	The metabolism of Ramelteon can be decreased when combined with Olaparib.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Ramelteon.	Approved
Omeprazole	The metabolism of Ramelteon can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of adverse effects can be increased when Ondansetron is combined with Ramelteon.	Approved
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Ramelteon.	Approved, Illicit
Orphenadrine	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Osanetant is combined with Ramelteon.	Investigational
Osimertinib	The serum concentration of Ramelteon can be increased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Ramelteon.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ramelteon.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ramelteon.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Ramelteon.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ramelteon.	Approved, Investigational, Vet Approved
Palbociclib	The serum concentration of Ramelteon can be increased when it is combined with Palbociclib.	Approved
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Ramelteon.	Approved
Pantoprazole	The metabolism of Ramelteon can be decreased when combined with Pantoprazole.	Approved
Paraldehyde	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.	Approved, Investigational
Peginterferon alfa-2b	The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon.	Approved, Vet Approved
Pentobarbital	The metabolism of Ramelteon can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved
Perazine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Perazine.	Investigational
Perospirone	The risk or severity of adverse effects can be increased when Perospirone is combined with Ramelteon.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Ramelteon.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Ramelteon.	Approved
Phenobarbital	The metabolism of Ramelteon can be increased when combined with Phenobarbital.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ramelteon.	Approved
Phenytoin	The metabolism of Ramelteon can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Ramelteon.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Ramelteon.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Ramelteon is combined with Piritramide.	Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Ramelteon is combined with Pizotifen.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.	Approved
Posaconazole	The serum concentration of Ramelteon can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	Ramelteon may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Pramocaine is combined with Ramelteon.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Prazepam is combined with Ramelteon.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Ramelteon.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Ramelteon.	Approved
Primidone	The metabolism of Ramelteon can be increased when combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Ramelteon.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Promethazine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Ramelteon.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Propoxycaine is combined with Ramelteon.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon.	Approved
PSD502	The risk or severity of adverse effects can be increased when PSD502 is combined with Ramelteon.	Investigational
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Ramelteon.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Ramelteon is combined with Raclopride.	Investigational
Ranolazine	The metabolism of Ramelteon can be decreased when combined with Ranolazine.	Approved, Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Ramelteon.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Ramelteon.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Ramelteon.	Approved
Rifabutin	The metabolism of Ramelteon can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Ramelteon can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Ramelteon can be increased when combined with Rifapentine.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Ramelteon is combined with Ritanserin.	Investigational
Ritonavir	The serum concentration of Ramelteon can be increased when it is combined with Ritonavir.	Approved, Investigational
Romifidine	The risk or severity of adverse effects can be increased when Romifidine is combined with Ramelteon.	Vet Approved
Ropinirole	Ramelteon may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ramelteon.	Approved
Rotigotine	Ramelteon may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Ramelteon.	Approved
Saquinavir	The serum concentration of Ramelteon can be increased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Ramelteon.	Approved, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Sertindole is combined with Ramelteon.	Approved, Withdrawn
Sertraline	The metabolism of Ramelteon can be decreased when combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ramelteon.	Approved, Vet Approved
Sildenafil	The metabolism of Ramelteon can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Ramelteon can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Ramelteon can be increased when it is combined with Simeprevir.	Approved
Sodium oxybate	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.	Approved
St. John's Wort	The serum concentration of Ramelteon can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Ramelteon can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.	Approved, Investigational
Sulfadiazine	The serum concentration of Ramelteon can be increased when it is combined with Sulfadiazine.	Approved, Vet Approved
Sulfisoxazole	The serum concentration of Ramelteon can be increased when it is combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Ramelteon.	Approved
Suvorexant	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Ramelteon is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Ramelteon is combined with Tasimelteon.	Approved
Telaprevir	The serum concentration of Ramelteon can be increased when it is combined with Telaprevir.	Withdrawn
Telithromycin	The serum concentration of Ramelteon can be increased when it is combined with Telithromycin.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Ramelteon.	Approved
Tenofovir disoproxil	The metabolism of Ramelteon can be decreased when combined with Tenofovir.	Approved, Investigational
Teriflunomide	The serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Tetracaine is combined with Ramelteon.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ramelteon.	Investigational
Thalidomide	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Ramelteon can be decreased when combined with Theophylline.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Ramelteon.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Ramelteon.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Ramelteon.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Ramelteon.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Ramelteon is combined with Tiapride.	Approved, Investigational
Ticlopidine	The metabolism of Ramelteon can be decreased when combined with Ticlopidine.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Tiletamine is combined with Ramelteon.	Vet Approved
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon.	Approved
Tocilizumab	The serum concentration of Ramelteon can be decreased when it is combined with Tocilizumab.	Approved
Tolbutamide	The serum concentration of Ramelteon can be increased when it is combined with Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Ramelteon.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Topiramate is combined with Ramelteon.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Ramelteon.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ramelteon.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramelteon.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Ramelteon.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Ramelteon.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ramelteon.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Trimipramine is combined with Ramelteon.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Triprolidine is combined with Ramelteon.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Ramelteon.	Approved, Investigational
Vemurafenib	The serum concentration of Ramelteon can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	The metabolism of Ramelteon can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Ramelteon can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Ramelteon is combined with Vigabatrin.	Approved
Voriconazole	The serum concentration of Ramelteon can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Vortioxetine is combined with Ramelteon.	Approved
Xylazine	The risk or severity of adverse effects can be increased when Xylazine is combined with Ramelteon.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Ramelteon is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Ramelteon is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Ramelteon can be decreased when combined with Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Zolazepam is combined with Ramelteon.	Vet Approved
Zolpidem	Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Ramelteon.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Zotepine is combined with Ramelteon.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ramelteon.	Approved, Investigational

Food Interactions

Avoid alcohol.
Do not take with or immediately after a high-fat meal.

References

Synthesis Reference

Vinod Kumar Kansal, Dhirenkumar N. Mistry, Sanjay L. Vasoya, "Intermediates and processes for the synthesis of Ramelteon." U.S. Patent US20080242877, issued October 02, 2008.

US20080242877

General References

Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265 ]
Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178 ]
Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703 ]
Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111 ]
Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650 ]
Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19. [PubMed:18729542 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15115
PubChem Compound	208902
PubChem Substance	46505923
ChemSpider	181000
BindingDB	50118470
ChEBI	109549
ChEMBL	CHEMBL1218
Therapeutic Targets Database	DAP000070
PharmGKB	PA164744896
IUPHAR	1356
Guide to Pharmacology	1356
RxList	http://www.rxlist.com/cgi/generic4/rozerem.htm
Drugs.com	http://www.drugs.com/cdi/ramelteon.html
Wikipedia	Ramelteon

ATC Codes

N05CH02 — Ramelteon

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Download (2.36 MB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Sleeplessness	1
1	Completed	Basic Science	Marijuana Dependence	1
1	Completed	Prevention	Sleeplessness	1
2	Completed	Treatment	Chronic Insomnia	2
2	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
2	Completed	Treatment	Drug Abuse	1
2	Completed	Treatment	Sleep Apnea, Obstructive	1
2	Completed	Treatment	Sleep Disorder	1
2	Completed	Treatment	Sleep Disorders, Circadian Rhythm	1
2	Completed	Treatment	Sleep Initiation and Maintenance Disorders	2
2	Completed	Treatment	Minor burns / Sleep	1
2	Recruiting	Prevention	Amnestic / Cognitive Disorders / Delayed Emergence From Anesthesia / Delirium / Delirium, Dementia / Delirium, Dementia, Amnestic, Cognitive Disorders	1
2	Recruiting	Treatment	Tobacco Use Disorders	1
2	Terminated	Prevention	Migraine With Aura / Migraine Without Aura / Migraines	1
3	Completed	Treatment	Balance	1
3	Completed	Treatment	Chronic Insomnia	5
3	Completed	Treatment	Obstructive Sleep Apnea (OSA) / Sleeplessness	1
3	Completed	Treatment	Sleep Initiation and Maintenance Disorders	2
3	Completed	Treatment	Sleeplessness	1
3	Completed	Treatment	Transient Insomnia	1
3	Terminated	Treatment	Asthma Bronchial / Sleeplessness	1
3	Terminated	Treatment	Bipolar Disorder (BD)	1
3	Terminated	Treatment	Bipolar Disorder (BD) / Sleeplessness	1
3	Terminated	Treatment	Chronic Insomnia	1
3	Terminated	Treatment	Major Depressive Disorder (MDD) / Sleeplessness	1
3	Unknown Status	Treatment	Chronic Insomnia / Gastroesophageal Reflux Disease	1
3	Withdrawn	Treatment	Bipolar Disorder (BD)	1
4	Completed	Treatment	ADHD With Sleep Onset Insomnia	1
4	Completed	Treatment	Bipolar Disorder (BD)	1
4	Completed	Treatment	Chronic Insomnia	2
4	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Completed	Treatment	Circadian Dysregulation	1
4	Completed	Treatment	Quadriplegia / Sleep disorders and disturbances / Sleeplessness / Spinal Cord Injuries (SCI)	1
4	Completed	Treatment	REM Sleep Behavior Disorder	1
4	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders	1
4	Completed	Treatment	Seasonal Affective Disorder (SAD)	1
4	Completed	Treatment	Sleep Deprivation	1
4	Completed	Treatment	Sleeplessness	2
4	Not Yet Recruiting	Not Available	Delirium	1
4	Not Yet Recruiting	Prevention	Delirium in Old Age	1
4	Recruiting	Prevention	Delirium	1
4	Recruiting	Treatment	Liver Cirrhosis	1
4	Recruiting	Treatment	Major Depressive Disorder (MDD) / Sleeplessness	1
4	Recruiting	Treatment	Schizophrenic Disorders	1
4	Terminated	Treatment	Chronic Insomnia	1
4	Terminated	Treatment	Migrainous Headache	1
4	Terminated	Treatment	Parkinson's Disease (PD)	1
4	Unknown Status	Treatment	Brain Injury / Sleeplessness	1
4	Unknown Status	Treatment	Sleeplessness	1
Not Available	Completed	Not Available	Sleeplessness	2
Not Available	Completed	Basic Science	Healthy Volunteers	1
Not Available	Completed	Diagnostic	Obstructive Sleep Apnea (OSA)	1
Not Available	Not Yet Recruiting	Prevention	Delirium / Sleep Deprivation	1
Not Available	Terminated	Treatment	Pain, Neuropathic	1
Not Available	Terminated	Treatment	Panic Disorders / Sleeplessness	1
Not Available	Terminated	Treatment	Parkinsonism / REM Behavior Disorder	1
Not Available	Withdrawn	Treatment	Circadian Dysregulation / Diffuse Lewy Body Disease / Huntington's Disease (HD) / Parkinson's Disease (PD) / Sleep disorders and disturbances	1

Pharmacoeconomics

Manufacturers

Takeda global research development center inc

Packagers

Dosage forms

Form	Route	Strength
Tablet, film coated	Oral	8 mg/1

Prices

Unit description	Cost	Unit
Rozerem 8 mg tablet	5.17USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6034239	No	1999-07-22	2019-07-22	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	2.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0164 mg/mL	ALOGPS
logP	3.03	ALOGPS
logP	2.57	ChemAxon
logS	-4.2	ALOGPS
pKa (Strongest Acidic)	15.82	ChemAxon
pKa (Strongest Basic)	-0.4	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	38.33 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	75.52 m³·mol^-1	ChemAxon
Polarizability	29.99 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9934
Caco-2 permeable	+	0.5893
P-glycoprotein substrate	Substrate	0.5211
P-glycoprotein inhibitor I	Non-inhibitor	0.8548
P-glycoprotein inhibitor II	Non-inhibitor	0.7877
Renal organic cation transporter	Non-inhibitor	0.6381
CYP450 2C9 substrate	Non-substrate	0.7876
CYP450 2D6 substrate	Non-substrate	0.6392
CYP450 3A4 substrate	Substrate	0.512
CYP450 1A2 substrate	Inhibitor	0.7314
CYP450 2C9 inhibitor	Non-inhibitor	0.6471
CYP450 2D6 inhibitor	Non-inhibitor	0.5916
CYP450 2C19 inhibitor	Inhibitor	0.8314
CYP450 3A4 inhibitor	Non-inhibitor	0.9196
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.7763
Ames test	Non AMES toxic	0.7016
Carcinogenicity	Non-carcinogens	0.8206
Biodegradation	Ready biodegradable	0.6635
Rat acute toxicity	2.1034 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7898
hERG inhibition (predictor II)	Inhibitor	0.5

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-0nmi-2980000000-5ee1e7ec83e5c4578dfe	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.

Kingdom

Super Class

Class

Sub Class

Direct Parent

Alternative Parents

Coumarans / Alkyl aryl ethers / Secondary carboxylic acid amides / Oxacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

Substituents

Indane / Coumaran / Alkyl aryl ether / Carboxamide group / Secondary carboxylic acid amide / Oxacycle / Organoheterocyclic compound / Ether / Carboxylic acid derivative / Hydrocarbon derivative

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Targets

Details

1. Melatonin receptor type 1B

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: multitarget

General Function:: Melatonin receptor activity
Specific Function:: High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.
Gene Name:: MTNR1B
Uniprot ID:: P49286
Uniprot Name:: Melatonin receptor type 1B
Molecular Weight:: 40187.895 Da

References

Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10. [PubMed:15695169 ]
Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265 ]
Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96. [PubMed:17389558 ]
Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650 ]
Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24. [PubMed:16730121 ]
Authors unspecified: Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8. [PubMed:15869323 ]
Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178 ]
Miyamoto M: [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. [PubMed:19768947 ]
Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703 ]
Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111 ]
Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. [PubMed:17015817 ]
Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. [PubMed:17803013 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Melatonin receptor type 1A

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: multitarget

General Function:: Organic cyclic compound binding
Specific Function:: High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.
Gene Name:: MTNR1A
Uniprot ID:: P48039
Uniprot Name:: Melatonin receptor type 1A
Molecular Weight:: 39374.315 Da

References

Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10. [PubMed:15695169 ]
Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265 ]
Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96. [PubMed:17389558 ]
Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650 ]
Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24. [PubMed:16730121 ]
Authors unspecified: Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8. [PubMed:15869323 ]
Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178 ]
Miyamoto M: [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. [PubMed:19768947 ]
Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703 ]
Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111 ]
Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. [PubMed:17015817 ]
Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. [PubMed:17803013 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. Cytochrome P450 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:: CYP1A2
Uniprot ID:: P05177
Uniprot Name:: Cytochrome P450 1A2
Molecular Weight:: 58293.76 Da

References

Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852 ]

Details

2. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Uniprot Name:: Cytochrome P450 2C19
Molecular Weight:: 55930.545 Da

References

Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852 ]

Details

3. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

References

Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852 ]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:34

Structure for DB00980 (Ramelteon)

Targets

References

References

Enzymes

References

References

References